SCHEMBL3208385

SCHEMBL3208385

CCCCCCCCCCCCC(CCCCCCCCCCCC)(CCCCCCCCCCCCCO)C(CCCCCCCCCCCC)(CCCCCCCCCCCC)C(CCCCCCCCCCCC)(CCCCCCCCCCCC)C(CCCCCCCCCCCC)(CCCCCCCCCCCC)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.42
ALDH1A1 P00352 3/20 0.42
LMNA P02545 2/20 0.42
HSD17B10 Q99714 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP4F2 P78329 2/20 0.39
CYP4A11 Q02928 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CES2 O00748 1/20 0.35
PPARG P37231 5/20 0.33
PPARD Q03181 5/20 0.33
PPARA Q07869 5/20 0.33
HDAC11 Q96DB2 4/20 0.33
GPR84 Q9NQS5 3/20 0.33
TLR2 O60603 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
FABP4 P15090 2/20 0.33
PTPN1 P18031 2/20 0.33
SLC22A6 Q4U2R8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4057603 0.93 CES2 (0.39) TSHRALDH1A1HSD17B10MEN1KMT2A
SCHEMBL2682265 0.93 CES2 (0.39) TSHRALDH1A1HSD17B10MEN1KMT2A
SCHEMBL5665231 0.93 CES2 (0.39) TSHRALDH1A1HSD17B10MEN1KMT2A
SCHEMBL5179328 0.93 CES2 (0.39) TSHRALDH1A1HSD17B10MEN1KMT2A
SCHEMBL5983660 0.93 CES2 (0.39) TSHRALDH1A1HSD17B10MEN1KMT2A
SCHEMBL5178373 0.92 CES2 (0.38) TSHRALDH1A1HSD17B10MEN1KMT2A
SCHEMBL9274885 0.89 CES2 (0.36) TSHRALDH1A1HSD17B10MEN1KMT2A
SCHEMBL28854780 0.88 CES2 (0.40) TSHRALDH1A1HSD17B10MEN1KMT2A
SCHEMBL15572971 0.88 CES2 (0.40) TSHRALDH1A1HSD17B10MEN1KMT2A
Acetic Acid SCHEMBL4292824 0.86 MEN1 (0.35) TSHRALDH1A1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100092416-A1 METHOD FOR THE COSMETIC TREATMENT OF KERATIN MATERIALS L'OREAL S.A. (FR) 2010-04-15 US disclosed
US-20100061953-A1 METHOD FOR THE COSMETIC TREATMENT OF KERATINIC MATERIALS AND COMPOSITION CONTAINING A GRAFTED AMINO ACID POLYMER L'OREAL S.A. (FR) 2010-03-11 US disclosed
US-20050008595-A1 Cosmetic compositions with optical variability L'OREAL S.A. (FR) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100061953-A1 METHOD FOR THE COSMETIC TREATMENT OF KERATINIC MATERIALS AND COMPOSITION CONTAINING A GRAFTED AMINO ACID POLYMER KRT18, CUTA, AADAT TSHR 3925/4885ALDH1A1 2170/4885LMNA 1910/4885
US-20100092416-A1 METHOD FOR THE COSMETIC TREATMENT OF KERATIN MATERIALS KRT18, CUTA, OAT TSHR 3209/4885ALDH1A1 2185/4885LMNA 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.